942 results match your criteria Current Treatment Options in Oncology[Journal]


Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.

Curr Treat Options Oncol 2019 Feb 15;20(3):20. Epub 2019 Feb 15.

Department of Head and Neck Oncologic Surgery, Head and Neck Institute, Cleveland Clinic, 9500 Euclid Avenue, A-71, Cleveland, OH, 44195, USA.

Opinion Statement: Despite an overall decline in the incidence of tobacco-related cancers, human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) of the oropharynx is on the rise. The prognosis of HPV-related oropharynx cancer (HPV-OPC) is generally favorable even in locoregionally advanced disease, and a variety of treatment options are available. Though the primary treatment modality of choice remains definitive radiation (RT), surgical resection followed by appropriate adjuvant therapy remains an option, especially in those patients who may not be favorable candidates for definitive radiotherapy, particularly when concurrent chemotherapy is warranted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0620-yDOI Listing
February 2019

Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Curr Treat Options Oncol 2019 Feb 14;20(2):18. Epub 2019 Feb 14.

Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 432, Houston, TX, 77030, USA.

Opinion Statement: Recent advances in immunology have extended into the mesothelioma field. To date, only Japan has given regulatory approval to salvage nivolumab in chemo-refractory mesothelioma patients. The USA has included in the NCCN guidelines that pembrolizumab (in programmed death ligand 1 (PD-L1) immunohistochemistry (IHC)-positive patients) and nivolumab with or without ipilimumab (whatever the PD-L1 status is) are accepted salvage therapies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0613-x
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0613-xDOI Listing
February 2019
1 Read

Updates on Minimally Invasive Surgery in Non-Small Cell Lung Cancer.

Authors:
Norihiko Ikeda

Curr Treat Options Oncol 2019 Feb 11;20(2):16. Epub 2019 Feb 11.

Department of Thoracic Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

Opinion Statement: Video-assisted thoracic surgery (VATS) has become widely used since the 1990s and has become a standard treatment approach mainly for early-stage non-small cell lung cancer. The few randomized controlled trials providing evidence of the effectiveness of VATS lobectomy at present are supported by a large number of propensity-matched studies, several high-quality meta-analyses, and outcome studies. These studies provide comprehensive data demonstrating the lower morbidity, shorter chest tube duration, and shorter hospital stay of VATS than thoracotomy during the postoperative course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0614-9DOI Listing
February 2019
1 Read

Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Curr Treat Options Oncol 2019 Feb 11;20(2):15. Epub 2019 Feb 11.

Department of Pathology, University of Chicago, Chicago, IL, USA.

Opinion Statement: Acute myeloid leukemia (AML) patients with a complex karyotype (CK-AML) show at least 3 unrelated clonal cytogenetic abnormalities with notoriously poor outcome. Such cases fall into either AML with myelodysplasia-related changes or therapy-related AML in the current World Health Organization classification of AML. Allogeneic stem cell transplantation is one of the only treatment modalities that can provide a long-term survival benefit and is recommended as a consolidative treatment in patients who are able to achieve complete remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0612-yDOI Listing
February 2019
1 Read

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Curr Treat Options Oncol 2019 Feb 11;20(2):12. Epub 2019 Feb 11.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA.

Opinion Statement: Cisplatin has been established as an important agent in the neoadjuvant setting prior to radical cystectomy (RC) surgery for muscle-invasive urothelial cancer (MIUC) as well as in the unresectable or metastatic urothelial carcinoma (mUC) setting. Unfortunately, many patients in practice are felt to be "cisplatin-ineligible." Thus, it is vital that we develop treatment approaches and novel therapeutics for this population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0609-6
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0609-6DOI Listing
February 2019
8 Reads

Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients.

Curr Treat Options Oncol 2019 Feb 11;20(2):11. Epub 2019 Feb 11.

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Opinion Statement: Care delivery innovation is necessary to address the growing complexity of cancer care across specialties and integrate new diagnostics, treatments, and services into care delivery. Informed by Cancer Care Delivery Research (CCDR), multilevel intervention research, and other disciplines, this article describes the 4-step cancer care delivery innovation cycle. The cycle guides collaborative efforts of cancer clinicians, researchers, patients, and other stakeholders to systematically define care delivery problems and formulate, test, and implement care innovations to effectively address problems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0608-7DOI Listing
February 2019

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Curr Treat Options Oncol 2019 Feb 11;20(2):14. Epub 2019 Feb 11.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Opinion Statement: Nonmetastatic castration-resistant prostate cancer (nmCRPC) comprises a relatively narrow niche of advanced prostate cancer, but the treatment landscape for men with nmCRPC has drastically changed over the past year. Prior to the SPARTAN and PROSPER trials, men with nmCRPC were commonly treated with first-generation androgen receptor antagonists, such as bicalutamide or flutamide, or with estrogens or ketoconazole, none of which were associated with any proven survival benefit. The SPARTAN trial evaluated apalutamide versus placebo for men with nmCRPC and found that apalutamide significantly improved metastasis-free survival (MFS), the primary endpoint of this trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0611-zDOI Listing
February 2019
1 Read

Palliative Cancer Care in the Outpatient Setting: Which Model Works Best?

Authors:
David Hui

Curr Treat Options Oncol 2019 Feb 11;20(2):17. Epub 2019 Feb 11.

Department of Palliative Care, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Unit 1414 - 1515 Holcombe Blvd., Houston, TX, 77030, USA.

Opinion Statement: Multiple randomized controlled trials have underscored the importance of timely referral to palliative care for patients with advanced cancer. Outpatient palliative care can facilitate timely referral and is increasingly available in many cancer centers. The key question is which model of outpatient palliative care is optimal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0615-8DOI Listing
February 2019
1 Read

Diagnosis and Management of Basal Cell Carcinoma.

Authors:
Keiji Tanese

Curr Treat Options Oncol 2019 Feb 11;20(2):13. Epub 2019 Feb 11.

Department of Dermatology, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo, 160-8582, Japan.

Opinion Statement: Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0610-0
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0610-0DOI Listing
February 2019
2 Reads

Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors.

Curr Treat Options Oncol 2019 Feb 9;20(1):10. Epub 2019 Feb 9.

Pediatric Endocrinology, Emory Children's Center/Emory Pediatric Institute, 2015 Uppergate Drive, Room 232, Atlanta, GA, 30322, USA.

Opinion Statement: Pathologies of pediatric brain tumors are more varied than those diagnosed in adults and survival outcomes more optimistic. Therapies for pediatric brain tumors are also diverse and treatment options are expanding. The growing number of adult survivors of childhood brain tumors is quite diverse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0602-0DOI Listing
February 2019

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Curr Treat Options Oncol 2019 Feb 4;20(1). Epub 2019 Feb 4.

Department of Hematology and Medical Oncology, Moffitt Cancer Center/University of South Florida, 12902 USF Magnolia Dr, Tampa, FL, 33612, USA.

Opinion Statement: While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes. For this reason, the standard approach for eligible patients has been high-dose induction chemotherapy preferably with acute lymphoblastic leukemia (ALL)-based regimens followed by consolidation with allogeneic hematopoietic stem cell transplantation (alloHSCT). Unfortunately, many patients with this disease are elderly and/or frail and cannot tolerate this therapy, and the low-dose regimens being used in this population are generally not as effective. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0605-x
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0605-xDOI Listing
February 2019
3 Reads

The Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer: the European Perspective.

Curr Treat Options Oncol 2019 Jan 26;20(1). Epub 2019 Jan 26.

Policlinico San Martino IRCCS, Largo R. Benzi 10, 16132, Genoa, Italy.

Opinion Statement: The International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration was created to pool data from different studies worldwide in order to assess whether a shorter duration of adjuvant treatment in colon cancer could maintain the expected benefit while reducing toxicity. The results of the IDEA trials were clinically relevant. They confirmed a two- to sixfold reduction in neurotoxicity for the shorter duration across trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0600-2DOI Listing
January 2019

Targeted Therapy and Immunotherapy for Melanoma in Japan.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Opinion Statement: Melanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution of systemic therapies for advanced melanoma, access to innovative agents is still restricted in many countries. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0607-8
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0607-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344396PMC
January 2019
8 Reads

First-Line Therapy for Metastatic Soft Tissue Sarcoma.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Hematology and Oncology, Mayo Clinic, 5881 E Mayo Blvd., Phoenix, AZ, 85054, USA.

Opinion Statement: Soft tissue sarcomas are rare cancers with an expected incidence of about 14,000 new cases in 2018, and account for less than 1% of all cancers. It includes in excess of 75 heterogeneous subtypes with varying biology, molecular aberrations, and variable response to treatment. Because of the rarity of these tumors and the many different subtypes, there is no large-scale data to guide treatment, and hence the need for a multidisciplinary individualized approach to treatment, preferably at a high-volume tertiary referral center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0606-9DOI Listing
January 2019

New Concepts of Treatment for Patients with Myelofibrosis.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA.

Opinion Statement: Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. Patients who discontinue ruxolitinib have a dismal outcome, and this is, therefore, an area of significant unmet need. Given the central role that JAK-signal transducer and activator of transcription (STAT) activation plays in disease pathogenesis, there have been many other JAK inhibitors tested, but most have been abandoned, for a variety of reasons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0604-yDOI Listing
January 2019
5 Reads

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0428, Houston, TX, 77030, USA.

Opinion Statement: With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the prognosis of patients has improved dramatically. Currently, the standard of care in the frontline setting for fit patients is TKI in combination with chemotherapy. Age-adjusted chemotherapy or corticosteroids alone have been used with TKIs in elderly patients with comorbidities with modest long-term benefit. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0603-z
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0603-zDOI Listing
January 2019
6 Reads

Therapeutic Intensification and Induction Chemotherapy for High-Risk Locally Advanced Squamous Cell Carcinoma.

Curr Treat Options Oncol 2019 Jan 11;20(2). Epub 2019 Jan 11.

Medical Oncology Department, Ospedale dell'Angelo, Venice, Italy.

Opinion Statement: The treatment of HNSCC has rapidly evolved over the past 30 years and multidisciplinary management is required, especially for locally advanced disease (LAHNSCC). Concomitant chemoradiation (cCRT) is the standard of care and cetuximab/RT (CET/RT) is an alternative treatment option, especially for patients unfit for concurrent cisplatin. Several intensification strategies have been explored to improve the outcome of the concomitant treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0599-4DOI Listing
January 2019
3 Reads

Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.

Curr Treat Options Oncol 2019 Jan 11;20(2). Epub 2019 Jan 11.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Opinion Statement: Globally, hepatocellular carcinoma (HCC) is a leading cause of cancer-related death and a malignancy with rising incidence. After sorafenib remaining the one and only FDA-approved therapy for the disease for many years, the past 2 years has seen the landscape of available treatments change dramatically. Multiple multi-targeted tyrosine kinases (TKIs) have demonstrated success and garnered FDA approval both in the first- (lenvatinib) and second-line (regorafenib) settings. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0601-1
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0601-1DOI Listing
January 2019
11 Reads

Immunotherapy Advances in Urothelial Carcinoma.

Curr Treat Options Oncol 2018 Dec 15;19(12):79. Epub 2018 Dec 15.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

Opinion Statement: Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0598-x
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0598-xDOI Listing
December 2018
9 Reads

Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?

Authors:
Antoine Italiano

Curr Treat Options Oncol 2018 Dec 7;19(12):78. Epub 2018 Dec 7.

Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33076, Bordeaux, France.

Opinion Statement: Soft-tissue sarcomas represent a heterogeneous group of diseases accounting for up to 1% of cancer in adults and 15% of cancer in children. Introduction of next-generation sequencing (NGS) technologies has allowed to gain additional insight into the genetic diversity and complexity of sarcomas, including the potential therapeutic implications of some genetic alterations.Two large studies have investigated the role of targeted NGS to identify actionable mutations in patients with soft-tissue sarcomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0589-yDOI Listing
December 2018
1 Read

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Curr Treat Options Oncol 2018 Nov 15;19(12). Epub 2018 Nov 15.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Dr. CPB 6.3279, Houston, TX, 77030, USA.

Opinion Statement: Use of poly(ADP-ribose) polymerase (PARP) inhibitors has greatly increased over the past 5 years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and primary peritoneal cancer). Olaparib and rucaparib currently have indications for treatment of recurrent BRCA mutant ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0572-7DOI Listing
November 2018
5 Reads

Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.

Curr Treat Options Oncol 2018 Nov 27;19(12):77. Epub 2018 Nov 27.

Medical Oncology Department, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University, No. 26 Yuan Cun Er Heng Road, Guangzhou, 510655, China.

Opinion Statement: Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs. 5-FU can be administered through a bolus injection or continuous infusion (cIV), with the latter becoming the preferred administration method and standard of care in recent years. Oral fluoropyrimidines were developed to overcome challenges associated with the IV administration of 5-FU, among which capecitabine has become the most widely used one. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0597-yDOI Listing
November 2018
9 Reads

Proton Therapy in Non-small Cell Lung Cancer.

Curr Treat Options Oncol 2018 Nov 27;19(12):76. Epub 2018 Nov 27.

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Opinion Statement: Non-small cell lung cancer (NSCLC) accounts for 85% of new lung cancer cases and has 5-year survival rates ranging from 92% in early-stage disease to as low as 13% in locally advanced cases. Radiation therapy is a key component in the treatment repertoire for NSCLC, where it is currently used alone or in combinations with chemotherapy and surgery. Despite the broad use of modern photon radiation techniques, as many as 25% of patients experience isolated locoregional recurrences, and toxicity has been proven to be a limiting factor in many cases. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0588-z
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0588-zDOI Listing
November 2018
8 Reads

Radical Trachelectomy for Early Stage Cervical Cancer.

Curr Treat Options Oncol 2018 Nov 19;19(12):75. Epub 2018 Nov 19.

Instituto Gyneco-Oncólogico, 252 San Jorge St, San Juan, PR, 00914, USA.

Opinion Statement: In patients with early-stage cervical cancer, radical hysterectomy and pelvic lymphadenectomy is the gold standard. However, this disease commonly affects women of childbearing age; thus an option to spare fertility is ideal. This option came to fruition in the early 90s when the Dargent procedure or radical trachelectomy was first reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0591-4DOI Listing
November 2018
2 Reads

Review of Immune Therapies Targeting Ovarian Cancer.

Curr Treat Options Oncol 2018 Nov 14;19(12):74. Epub 2018 Nov 14.

Division of Gynecologic Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland-Baltimore, 22 S. Greene Street S3AX31, Baltimore, MD, 21201, USA.

Opinion Statement: The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term "immunotherapy" envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0584-3DOI Listing
November 2018
6 Reads

Novel Surgical Strategies in the Treatment of Gynecological Malignancies.

Curr Treat Options Oncol 2018 Nov 9;19(12):73. Epub 2018 Nov 9.

Department of Surgical Oncology, Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Opinion Statement: The main advancement in the surgical treatment of early cervical cancer has been a de-escalation in the radical surgical approach of early stage disease. Similarly, sentinel lymph node detection with cervical tracer injection can be performed alone in microscopic tumors (stage IA) while additional lymphadenectomy is still performed in macroscopic tumors (IB1 and IIA). Parametrial resection has been progressively reduced in tumors less than 2 cm, and simple procedures, conservative (trachelectomy) or not (simple hysterectomy), are currently being evaluated in several phase III trials. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0582-5
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0582-5DOI Listing
November 2018
18 Reads

Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review.

Curr Treat Options Oncol 2018 Nov 9;19(12):72. Epub 2018 Nov 9.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1840 Old Spanish Trail, Box 1150, Houston, TX, 77054, USA.

Opinion Statement: Taste sensation is vital for a healthy body as it influences our food intake, acts as a defense mechanism and elicits pleasure. Majority of the head and neck cancer (HNC) patients undergoing radiotherapy suffer from altered taste function and often complain of inability to taste their food, reduced food intake, and weakness. However, there are not many studies conducted to assess this commonly reported side effect. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0580-7
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0580-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244914PMC
November 2018
6 Reads

Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.

Curr Treat Options Oncol 2018 Nov 6;19(12):71. Epub 2018 Nov 6.

A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria, Italy.

Opinion Statement: Indolent non-Hodgkin lymphomas (iNHL) are a heterogeneous group of pathologies characterized by a prolonged natural history and good response to treatment. They also have a tendency to relapse, in some cases with a worse prognosis. One of the main objectives in the newest clinical trials is to identify patients at high risk of relapse. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0594-1
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0594-1DOI Listing
November 2018
17 Reads

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.

Curr Treat Options Oncol 2018 Nov 5;19(12):70. Epub 2018 Nov 5.

Thorton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, 1215 Lee Street, Charlottesville, VA, 22902, USA.

Opinion Statement: Activity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0593-2
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0593-2DOI Listing
November 2018
13 Reads

Management of Advanced Small Bowel Cancer.

Curr Treat Options Oncol 2018 Nov 5;19(12):69. Epub 2018 Nov 5.

Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA, 90033, USA.

Opinion Statement: Small bower cancer is a rare disease, despite its incidence is increasing in the last decade. Both benign and malignant tumors can arise from the small intestine. The main histological cancer types are adenocarcinomas, neuroendocrine tumors, sarcomas, gastrointestinal stromal tumors (GISTs), and lymphomas. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0592-3
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0592-3DOI Listing
November 2018
11 Reads

Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits.

Curr Treat Options Oncol 2018 Oct 27;19(12):68. Epub 2018 Oct 27.

UPMC Hillman Cancer Center, 5150 Centre Avenue, 5th floor, Room 552, Pittsburgh, PA, 15232, USA.

Opinion Statement: In head and neck cancer, we continue to work towards a more personalized approach to treatment of patients, where analysis of a patient's tumor guides targeting of molecular or immunologic pathways. Critically important to this pursuit is a better understanding of the direct biologic effect of a drug or combination on the tumor microenvironment in humans, as well as biomarker discovery. These goals are consistent with the primary purpose of a "window of opportunity" trial and while conduct of these trials requires a careful balance of benefits and potential risks, to date these trials have been both feasible and safe in HNSCC in the curative intent setting. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0587-0
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0587-0DOI Listing
October 2018
13 Reads

Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.

Curr Treat Options Oncol 2018 Oct 27;19(12):67. Epub 2018 Oct 27.

Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, SRB 2nd Floor, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA.

Opinion Statement: Chronic myelomonocytic leukemia (CMML) is an aggressive myeloid neoplasm in which treatment strategies with the capacity to improve survival are currently lacking. Clinical features are heterogeneous and although the overall prognosis is poor, survival can vary significantly between individuals. This reflects the need for an individualized treatment approach which incorporates accurate risk stratification. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0581-6
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0581-6DOI Listing
October 2018
14 Reads

Improving Treatment for Myelodysplastic Syndromes Patients.

Curr Treat Options Oncol 2018 Oct 25;19(12):66. Epub 2018 Oct 25.

Department of Medicine, Columbia University Medical Center, Columbia University, Milstein Hospital Building, 6N-435, 177 Fort Washington Avenue, New York, NY, 10032, USA.

Opinion Statement: Aging is the most potent of carcinogens, especially for the bone marrow stem cell clonal disorders called myelodysplastic syndromes (MDS). Age-associated changes in the microenvironment or the soil of the bone marrow (BM) as well as in the cell or the seed provide a growth advantage for clonal myeloid cells. Slowly accumulating senescent cells which can no longer divide because they have reached the end of their proliferative life cycle, but which continue to produce metabolic debris, overwhelm the natural autophagy mechanisms resulting in pro-inflammatory changes in the BM soil. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0583-4
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0583-4DOI Listing
October 2018
10 Reads

Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.

Curr Treat Options Oncol 2018 Oct 25;19(12):63. Epub 2018 Oct 25.

UCLA Department of Hematology Oncology, 200 Medical Plaza, Suite 120, Los Angeles, CA, 90095, USA.

Opinion Statement: Acute myelogenous leukemia (AML) in the elderly is complex and has a poor prognosis, often characterized by higher risk cytogenetic and molecular features compared to that in younger patients. Rates of transplant have been limited by concern related to non-relapse mortality, as older patients have historically been considered medically unfit for the transplantation process. Reduced-intensity conditioning (RIC) for hematopoietic stem cell transplantation (HSCT) has been shown to provide similar efficacy to myeloablative methods, with decreased non-relapse mortality in the elderly and improved efficacy over non-transplant approaches with cytotoxic chemotherapy alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0577-2DOI Listing
October 2018
2 Reads

Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.

Curr Treat Options Oncol 2018 Oct 25;19(12):64. Epub 2018 Oct 25.

Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, Box 8076 660 S. Euclid Avenue, St. Louis, MO, 63110, USA.

Opinion Statement: Sarcomas are a heterogeneous group of rare malignancies that arise from mesenchymal cells and can occur anywhere in the body. Herein, the focus will be on one subtype of sarcoma that arises from adipocytic tissue, liposarcoma. Specifically, the review will focus on one type of liposarcoma, myxoid liposarcoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0590-5
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0590-5DOI Listing
October 2018
12 Reads

Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.

Curr Treat Options Oncol 2018 Oct 25;19(12):61. Epub 2018 Oct 25.

Division of Neuro-Oncology Mayo Clinic, Rochester, MN, USA.

Opinion Statement: The treatment paradigm for anaplastic glioma has shifted, owing to new diagnostic criteria and new phase III clinical trial evidence. In 2016, the WHO classification of brain tumors including diffuse gliomas was redefined to include molecular criteria, often supplanting the morphological appearance of the tumor cells. This was necessary as prognosis is more closely associated with molecular diagnosis than with morphology and grade. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0579-0
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0579-0DOI Listing
October 2018
20 Reads

Big Data in Head and Neck Cancer.

Curr Treat Options Oncol 2018 Oct 25;19(12):62. Epub 2018 Oct 25.

Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Opinion Statement: Head and neck cancers can be used as a paradigm for exploring "big data" applications in oncology. Computational strategies derived from big data science hold the promise of shedding new light on the molecular mechanisms driving head and neck cancer pathogenesis, identifying new prognostic and predictive factors, and discovering potential therapeutics against this highly complex disease. Big data strategies integrate robust data input, from radiomics, genomics, and clinical-epidemiological data to deeply describe head and neck cancer characteristics. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0585-2
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0585-2DOI Listing
October 2018
13 Reads

Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.

Authors:
John Charlson

Curr Treat Options Oncol 2018 Oct 25;19(12):65. Epub 2018 Oct 25.

Hematology/Oncology, Medical College of Wisconsin, Froedtert/MCW Cancer Center, 4th Floor, 9200 W. Wisconsin Ave., Milwaukee, WI, 53226, USA.

Opinion Statement: Soft tissue sarcoma (STS) is a heterogeneous disease, in terms of histologic subtype, body site of presentation, and behavior. Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal. Metastatic disease is associated with shortened survival. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0586-1
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0586-1DOI Listing
October 2018
7 Reads

Immunotherapy for Brain Tumors.

Curr Treat Options Oncol 2018 Oct 11;19(11):60. Epub 2018 Oct 11.

Lillian S. Wells Department of Neurosurgery, UF Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, PO Box 100265, Gainesville, FL, 32610, USA.

Opinion Statement: Despite aggressive surgery, radiation, and systemic chemotherapy, the prognosis for patients diagnosed with malignant brain tumors remains extremely poor, and standard treatments carry significant risks for long-term neurocognitive deficits. There is a clear and urgent need for the development of more effective treatments that will add minimal toxicity to standard therapies for invasive brain cancers. Cancer immunotherapy is a treatment modality that holds promise for the delivery of tumor-specific cytotoxicity, with the potential to eliminate brain tumor cells without harming the eloquent brain. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0576-3
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0576-3DOI Listing
October 2018
18 Reads

Head and Neck Cancer: Improving Patient-Reported Outcome Measures for Clinical Practice.

Curr Treat Options Oncol 2018 Oct 1;19(11):59. Epub 2018 Oct 1.

Health Sciences Faculty, Fernando Pessoa University (UFP-FCS), Rua Carlos da Maia, 296, 4200-150, Porto, Portugal.

Opinion Statement: Head and neck cancer includes a wide range of tumors that occur in several areas of the upper aerodigestive tract. Most head and neck cancer patients report treatment-related late effects (both physical and psycho-social). High-quality and patient-centered care in head and neck cancer depend on the understanding of the continuum patient's experience-the disease pathway. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0578-1
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0578-1DOI Listing
October 2018
17 Reads

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Curr Treat Options Oncol 2018 Sep 29;19(11):58. Epub 2018 Sep 29.

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong SAR.

Opinion Statement: Non-small cell lung cancer (NSCLC) harboring epidermal growth receptor (EGFR) mutation has distinct genomic characteristics. Introduction of systemic treatments that specifically targeted actionable EGFR mutations has changed the therapeutic paradigm in this group of patients. Moreover, newer generations of EGFR tyrosine-kinase inhibitors (EGFR-TKIs) with superior pharmacokinetics and pharmacodynamics properties such as dacomitinib and osimertinib, when used in the front-line setting, have shown more favorable treatment outcomes than first-generation EGFR-TKIs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0570-9DOI Listing
September 2018
3 Reads

Immunotherapy for Merkel Cell Carcinoma.

Curr Treat Options Oncol 2018 Sep 20;19(11):57. Epub 2018 Sep 20.

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.

Opinion Statement: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin, with frequent recurrences, metastasis, and a high mortality rate. For primary or locoregional MCC, a wide local excision followed by radiation therapy is the basic treatment modality for preventing recurrence at the primary site and involved lymph nodes. Cytotoxic chemotherapy has been commonly used to treat patients with metastatic MCC, but not as an adjuvant therapy for high-risk resected MCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0574-5DOI Listing
September 2018
2 Reads

Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions.

Curr Treat Options Oncol 2018 Sep 20;19(11):56. Epub 2018 Sep 20.

Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Opinion Statement: Dermatoscopy (dermoscopy) improves the diagnosis of benign and malignant cutaneous neoplasms in comparison with examination with the unaided eye and should be used routinely for all pigmented and non-pigmented cutaneous neoplasms. It is especially useful for the early stage of melanoma when melanoma-specific criteria are invisible to the unaided eye. Preselection by the unaided eye is therefore not recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0573-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153581PMC
September 2018
3 Reads

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Curr Treat Options Oncol 2018 Sep 19;19(11):55. Epub 2018 Sep 19.

Department of Surgery, Duke University, Durham, NC, 27710, USA.

Opinion Statement: This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0575-4DOI Listing
September 2018
5 Reads

Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.

Curr Treat Options Oncol 2018 Sep 18;19(11):54. Epub 2018 Sep 18.

Memorial Sloan Kettering Cancer Center, 300 East 66th Street, office 1305, New York, NY, 10065, USA.

Opinion Statement: Low-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer, accounting for approximately 10% of cases of serous ovarian cancer. Patients typically present at a younger age have a protracted clinical course with survival for those with recurrent disease nearing 10 years, and have a high prevalence of somatic (tumor-specific) mutations affecting the mitogen-activated protein kinase (MAPK) pathway. Initial treatment of patients with stage IC-IV disease is similar to that of high-grade serous ovarian cancer with surgery and platinum/taxane-based chemotherapy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0571-8
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0571-8DOI Listing
September 2018
3 Reads

Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.

Authors:
Roopesh Kansara

Curr Treat Options Oncol 2018 Sep 10;19(11):52. Epub 2018 Sep 10.

Department of Internal Medicine, Section of Medical Oncology/Hematology, CancerCare Manitoba, University of Manitoba, 409 Tache Avenue, Winnipeg, MB, R2H 2A6, Canada.

Opinion Statement: Central nervous system (CNS) relapse is an undesirable event in the course of patients with diffuse large B cell lymphoma (DLBCL) with a median survival of approximately 6 months following CNS relapse. CNS prophylaxis for the prevention of CNS recurrence, in addition to the standard R-CHOP chemotherapy, is thus preferable. For an overall relapse risk of 2-5%, administration of CNS-directed therapies for all patients with DLBCL is unnecessary and prophylaxis should be targeted for the high-risk patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0569-2
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0569-2DOI Listing
September 2018
7 Reads

Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.

Curr Treat Options Oncol 2018 Sep 10;19(11):53. Epub 2018 Sep 10.

Department of Internal Medicine, Division of Hematology & Oncology, University of Michigan, 1500 E. Medical Center Drive, 7217 CC, Ann Arbor, MI, 48109, USA.

Opinion Statement: Approximately 15% of the over 220,000 new lung cancers diagnosed each year in the USA are small cell lung cancer (SCLC). The standard of care for SCLC patients has not changed for many years. Therefore, there remains a need to evaluate novel drugs for the management of SCLC patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0568-3
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0568-3DOI Listing
September 2018
11 Reads

Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers.

Curr Treat Options Oncol 2018 Sep 7;19(10):51. Epub 2018 Sep 7.

Department of Radiation Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, 1665 Aurora Court, Suite 1032 MS F706, Aurora, CO, 80045, USA.

Opinion Statement: Assessing the quality of health care delivered is a priority across medical specialties, but it is particularly critical for radiation oncology, a field with rapid introduction of new technologies and treatment paradigms. Deviation from acceptable standards can lead to delivery of inferior therapies and medical errors that can directly compromise patient clinical outcome, thus leading to disparities in quality of care. Professional oncologic specialty societies often take ownership of standardizing best practices by issuing evidence-based disease-specific consensus guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0564-7DOI Listing
September 2018
3 Reads

Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.

Curr Treat Options Oncol 2018 Sep 1;19(10):50. Epub 2018 Sep 1.

Department of Medicine, Hematology/Oncology, Blood and Marrow Transplantation, University of Arizona, Tucson, AZ, 85724, USA.

Opinion Statement: R-CHOP has been the standard of care for diffuse large B cell lymphoma (DLBCL), curing approximately 60% of patients for more than 2 decades. However, the optimal treatment of patients who are too frail to tolerate this regimen and/or are not candidates for anthracycline therapy continues to be debated. MInT and GELA trials established addition of rituximab to CHOP in DLBCL but excluded patients older than 80 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0565-6DOI Listing
September 2018
3 Reads